Tilray Brands deepens its commitment to Europe's regulated medical cannabis sector with the launch of Tilray Medical Italia, a strategic venture with local partner Molteni Farmaceutici. The move comes as the company seeks to stabilize its growth narrative amid significant stock market volatility.
Europe relies on China for the rare earth elements essential in transition technologies, but it's making a late bid to end dependency.
The Eurozone economy expanded by 1.5% in 2025, outpacing forecasts despite ongoing trade tensions with the US, as a recovery in Germany and robust growth in Spain helped offset a slowdown in France.
French regulators have greenlit MARA Holdings' takeover of EDF's data center unit Exaion, imposing strict conditions on energy use and data protection. The deal marks a significant, albeit tightly supervised, expansion of the bitcoin miner's European ambitions into high-performance computing.
Major European neobanks like Revolut, Monzo, and bunq are renewing their push for a U.S. banking license, betting on regulatory shifts and market potential. Yet, the path is fraught with complexity, geopolitical uncertainty, and fierce competition.
The Supreme Court of British Columbia has granted final approval for Coeur Mining's acquisition of New Gold, moving the deal into its final regulatory phase. The transaction, poised to significantly expand Coeur's precious metals footprint, advances as the miner's stock shows considerable strength over the past year.
After a decade of development and multiple clinical setbacks, Sanofi's venglustat has met its primary goal in a Phase 3 trial for Type 3 Gaucher disease, offering new hope for neurological symptoms. The drug, however, failed a separate late-stage study for Fabry disease.
Beijing has lowered punitive tariffs on key EU dairy products, offering some relief to exporters like Arla and Lactalis. While welcomed as a de-escalation, European trade bodies argue the remaining duties are unjustified and call for continued negotiations to resolve the trade dispute.
Despite crypto market turmoil and mounting unrealized losses, BitMine Immersion Technologies made its largest weekly Ethereum purchase of the year, as Chairman Tom Lee points to a divergence between price action and robust on-chain activity.
Bishkek moves to engage Brussels after reports emerge that the EU is preparing to deploy its new anti-circumvention tool, targeting Kyrgyzstan's role as a conduit for goods to sanctioned Russia.
A damning report from the EU's financial watchdog reveals the bloc's struggle to secure the minerals essential for its climate goals, highlighting failed trade deals, stalled recycling, and persistent over-reliance on external suppliers.
Despite sitting on over $6 billion in unrealized losses, publicly-listed crypto firm BitMine Immersion Technologies continues its aggressive accumulation of Ethereum, viewing the price slump as a strategic buying opportunity.
The CoinDesk 20 Index, a key benchmark for the digital asset market, fell sharply over the weekend, with every constituent in the red. Ethereum's 13.9% drop was a primary driver of the downturn.
A damning report from the European Court of Auditors reveals the bloc is falling dangerously behind in securing the lithium, cobalt, and nickel needed for its energy transition, leaving climate goals and strategic autonomy in jeopardy.
Prominent crypto analyst Tom Lee faces a wave of skepticism after his aggressive price predictions for Ethereum and Bitcoin fail to materialize amid a market downturn, sparking debate over the role of high-profile forecasts in volatile markets.
Tesla's sales decline in Europe continues despite new lower-cost models, while industry buzz swirls around a hotly denied report of potential Ford-Xiaomi collaboration. Meanwhile, U.S. dealers show surprising pragmatism toward the EV transition.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
